Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: Implications for parkinson's disease

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Wey, Margaret Chia Ying ^a,b   Fernandez, Elizabeth ^a,b,c   Martinez, Paul Anthony ^b   Sullivan, Patricia ^d   Goldstein, David S ^d   Strong, Randy ^a,b,c  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETALDEHYDE; 4 HYDROXYNONENAL; ALDEHYDE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ALDEHYDE DEHYDROGENASE ISOENZYME 2; BENSERAZIDE; DOPAMINE; LEVODOPA; OXIDOREDUCTASE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; 3,4 DIHYDROXYPHENYLACETIC ACID; 3,4-DIHYDROXYPHENYLACETALDEHYDE; ALDEHYDE DEHYDROGENASE; DRUG DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG RESPONSE; GAIT; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; ROTAROD TEST; SUBSTANTIA NIGRA; ANIMAL; BODY WEIGHT; CHEMISTRY; COGNITIVE DEFECT; CYTOSOL; DEGENERATIVE DISEASE; DISEASE MODEL; ENZYMOLOGY; FEMALE; GENETICS; GENOTYPE; METABOLISM; MITOCHONDRION; NERVE CELL; PHYSIOLOGY; TIME; TRANSGENIC MOUSE;

ANIMALIA; MUS;

3,4-DIHYDROXYPHENYLACETIC ACID; ALDEHYDE DEHYDROGENASE; ANIMALS; BODY WEIGHT; COGNITION DISORDERS; CYTOSOL; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; GENOTYPE; MALE; MICE; MICE, TRANSGENIC; MITOCHONDRIA; NAD; NEURODEGENERATIVE DISEASES; NEURONS; PARKINSON DISEASE; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84857466337     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031522     Document Type: Article

References (65)

1. Maetzler W, Liepelt I, Berg D, (2009) Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurology 8: 1158-1171.
2. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
3. Carlsson A, Lindqvist M, Magnusson TOR, (1957) 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists. Nature 180: 1200.
4. Schulz JB, (2008) Update on the pathogenesis of Parkinson's disease. Journal of Neurology 255 (Suppl 5): 3-7.
5. Marchitti SA, Deitrich RA, Vasiliou V, (2007) Neurotoxicity and Metabolism of the Catecholamine-Derived 3,4-Dihydroxyphenylacetaldehyde and 3,4-Dihydroxyphenylglycolaldehyde: The Role of Aldehyde Dehydrogenase. Pharmacological Reviews 59: 125-150.
6. Jinsmaa Y, Florang VR, Rees JN, Mexas LM, Eckert LL, et al. (2011) Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease. Chemico-Biological Interactions 192: 118-121.
7. Mattammal MB, Chung HD, Strong R, Hsu FF, (1993) Confirmation of a dopamine metabolite in parkinsonian brain tissue by gas chromatography-mass spectrometry. Journal of Chromatography 614: 205-212.
8. Qin Z, Hu D, Han S, Reaney SH, Di Monte DA, et al. (2007) Effect of 4-Hydroxy-2-nonenal Modification on α-Synuclein Aggregation. Journal of Biological Chemistry 282: 5862-5870.
9. Burke W, Kumar V, Pandey N, Panneton W, Gan Q, et al. (2008) Aggregation of α-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathologica 115: 193-203.
10. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, et al. (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America 93: 2696-2701.
11. Goldstein DS, Sullivan P, Holmes C, Kopin IJ, Basile MJ, et al. (2011) Catechols in post-mortem brain of patients with Parkinson disease European. Journal of Neurology 18: 703-710.
12. Vasiliou V, Nebert DW, (2005) Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Human Genomics 2: 138-143.
13. McCaffery P, Dräger UC, (1994) High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system. Proceedings of the National Academy of Sciences of the United States of America 91: 7772-7776.
14. Galter D, Buervenich S, Carmine A, Anvret M, Olson L, (2003) ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia. Neurobiology of Disease 14: 637-647.
15. Westerlund M, Galter D, Carmine A, Olson L, (2005) Tissue- and species-specific expression patterns of class I, III, and IV Adh and Aldh1 mRNAs in rodent embryos. Cell and Tissue Research 322: 227-236.
16. Kamino K, Nagasaka K, Imagawa M, Yamamoto H, Yoneda H, et al. (2000) Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population. Biochemical and Biophysical Research Communications 273: 192-196.
17. Picklo MJ, Olson SJ, Markesbery WR, Montine TJ, (2001) Expression and activities of aldo-keto oxidoreductases in Alzheimer disease. Journal of Neuropathology and Experimental Neurology 60: 686-695.
18. Hao PP, Chen YG, Wang JL, Wang XL, Zhang Y, (2011) Meta-analysis of aldehyde dehydrogenase 2 gene polymorphism and Alzheimer's disease in East Asians. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 38: 500-506.
19. Li SW, Lin T-S, Minteer S, Burke WJ, (2001) 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis. Molecular Brain Research 93: 1-7.
20. Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS, (2003) 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Research 989: 205-213.
21. Burke WJ, Li SW, Chung HD, Ruggiero DA, Kristal BS, et al. (2004) Neurotoxicity of MAO Metabolites of Catecholamine Neurotransmitters: Role in Neurodegenerative Diseases. NeuroToxicology 25: 101-115.
22. Mattammal MB, Haring JH, Chung HD, Raghu G, Strong R, (1995) An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Neurodegeneration 4: 271-281.
23. Lamensdorf I, Eisenhofer G, Harvey-White J, Hayakawa Y, Kirk K, et al. (2000) Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. Journal of Neuroscience Research 60: 552-558.
24. Wood PL, Khan MA, Kulow SR, Mahmood SA, Moskal JR, (2006) Neurotoxicity of reactive aldehydes: The concept of "aldehyde load" as demonstrated by neuroprotection with hydroxylamines. Brain Research 1095: 190-199.
25. Wood PL, Khan MA, Moskal JR, (2007) The concept of "aldehyde load" in neurodegenerative mechanisms: Cytotoxicity of the polyamine degradation products hydrogen peroxide, acrolein, 3-aminopropanal, 3-acetamidopropanal and 4-aminobutanal in a retinal ganglion cell line. Brain Research 1145: 150-156.
26. Panneton WM, Kumar VB, Gan Q, Burke WJ, Galvin JE, (2010) The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS ONE 5: e15251.
27. Wang B, Wang J, Zhou S, Tan S, He X, et al. (2008) The association of mitochondrial aldehyde dehydrogenase gene (ALDH2) polymorphism with susceptibility to late-onset Alzheimer's disease in Chinese. Journal of the Neurological Sciences 268: 172-175.
28. Grünblatt E, Zehetmayer S, Jacob CP, Müller T, Jost WH, et al. (2010) Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. Journal of Neural Transmission 117: 1387-1393.
29. Meredith GE, Kang UJ, (2006) Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Movement disorders: official journal of the Movement Disorder Society 21: 1595-1606.
30. Gispert S, Del Turco D, Garrett L, Chen A, Bernard DJ, et al. (2003) Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Molecular and cellular neurosciences 24: 419-429.
31. Zhou W, Milder JB, Freed CR, (2008) Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease. The Journal of Biological Chemistry 283: 9863-9870.
32. Rozas G, Lopez-Martin E, Guerra MJ, Labandeira-Garcia JL, (1998) The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. Journal of neuroscience methods 83: 165-175.
33. Stolze H, Kuhtz-Buschbeck JP, Drucke H, Johnk K, Illert M, et al. (2001) Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry 70: 289-297.
34. Lewis GN, Byblow WD, Walt SE, (2000) Stride length regulation in Parkinson's disease: the use of extrinsic, visual cues. Brain: a journal of neurology 123 (Pt 10): 2077-2090.
35. Morris ME, Iansek R, Matyas TA, Summers JJ, (1996) Stride length regulation in Parkinson's disease. Normalization strategies and underlying mechanisms. Brain: a journal of neurology 119 (Pt 2): 551-568.
36. Canavan AG, Passingham RE, Marsden CD, Quinn N, Wyke M, et al. (1990) Prism adaptation and other tasks involving spatial abilities in patients with Parkinson's disease, patients with frontal lobe lesions and patients with unilateral temporal lobectomies. Neuropsychologia 28: 969-984.
37. Schapira AH, Holt IJ, Sweeney M, Harding AE, Jenner P, et al. (1990) Mitochondrial DNA analysis in Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society 5: 294-297.
38. Hampton TG, Amende I, (2010) Treadmill Gait Analysis Characterizes Gait Alterations in Parkinson's Disease and Amyotrophic Lateral Sclerosis Mouse Models. Journal of Motor Behavior 42: 1-4.
39. Guillot TS, Asress SA, Richardson JR, Glass JD, Miller GW, (2008) Treadmill Gait Analysis Does Not Detect Motor Deficits in Animal Models of Parkinson's Disease or Amyotrophic Lateral Sclerosis. Journal of Motor Behavior 40: 568-577.
40. Amende I, Kale A, McCue S, Glazier S, Morgan J, et al. (2005) Gait dynamics in mouse models of Parkinson's disease and Huntington's disease. Journal of NeuroEngineering and Rehabilitation 2: 20.
41. Fleming SM, Salcedo J, Fernagut P-O, Rockenstein E, Masliah E, et al. (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 24: 9434-9440.
42. Lees AJ, (1986) L-dopa treatment and Parkinson's disease. The Quarterly journal of medicine 59: 535-547.
43. Jubault T, Monetta L, Strafella AP, Lafontaine AL, Monchi O, (2009) L-dopa medication in Parkinson's disease restores activity in the motor cortico-striatal loop but does not modify the cognitive network. PLoS ONE 4: e6154.
44. Center for Drug Evaluation and Research (2005) Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. U.S. Food and Drug Administration Rockville, Maryland, USA. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf. Accessed 2005 July 6.
45. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited. The FASEB Journal 22: 659-661.
46. Fleming SM, Salcedo J, Hutson CB, Rockenstein E, Masliah E, et al. (2006) Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein. Neuroscience 142: 1245-1253.
47. Trugman JM, James CL, Wooten GF, (1991) D1/D2 dopamine receptor stimulation by L-dopa. A [14C]-2-deoxyglucose autoradiographic study. Brain: a journal of neurology 114 (Pt 3): 1429-1440.
48. Zgaljardic DJ, Foldi NS, Borod JC, (2004) Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions. Journal of Neural Transmission 111: 1287-1301.
49. Owen AM, Sahakian BJ, Hodges JR, Summers BA, Polkey CE, et al. (1995) Dopamine-Dependent Frontostriatal Planning Deficits in Early Parkinson's Disease. Neuropsychology 9: 126-140.
50. McNamara RK, Skelton RW, (1993) The neuropharmacological and neurochemical basis of place learning in the Morris water maze. Brain research Brain research reviews 18: 33-49.
51. Lamberty Y, Gower AJ, (1993) Spatial processing and emotionality in aged NMRI mice: a multivariate analysis. Physiology & behavior 54: 339-343.
52. Tanila H, Bjorklund M, Riekkinen P Jr, (1998) Cognitive changes in mice following moderate MPTP exposure. Brain Research Bulletin 45: 577-582.
53. Schneider JS, Kovelowski CJ 2nd, (1990) Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Research 519: 122-128.
54. Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, et al. (2003) Positron Emission Tomography of Striatal Serotonin Transporters in Parkinson Disease. Arch Neurol 60: 1223-1229.
55. Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, et al. (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain: a journal of neurology 131: 120-131.
56. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y, (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Research 275: 321-328.
57. Mayeux R, Stern Y, Sano M, Williams JB, Cote LJ, (1988) The relationship of serotonin to depression in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society 3: 237-244.
58. Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ, (2010) Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 133: 3434-3443.
59. Fernandez E, Koek W, Ran Q, Gerhardt GA, France CP, et al. (2006) Monoamine Metabolism and Behavioral Responses to Ethanol in Mitochondrial Aldehyde Dehydrogenase Knockout Mice. Alcoholism: Clinical and Experimental Research 30: 1650-1658.
60. Anderson DW, Schray RC, Duester G, Schneider JS, (2011) Functional significance of aldehyde dehydrogenase ALDH1A1 to the nigrostriatal dopamine system. Brain Research 1408: 81-87.
61. Chen J, Wang L, Chen Y, Sternberg P, Cai J, (2009) Phosphatidylinositol 3 kinase pathway and 4-hydroxy-2-nonenal-induced oxidative injury in the RPE. Investigative Ophthalmology & Visual Science 50: 936-942.
62. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F, (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415-55.
63. Duester G, (2001) Genetic dissection of retinoid dehydrogenases. Chemico-Biological Interactions 130-132: 469-480.
64. Team RDC (2011) R: A Language and Environment for Statistical Computing. Vienna, Austria R Foundation for Statistical Computing. Available: http://www.R-project.org.
65. Pinheiro J, Bates D, DebRoy S, Sarkar D, Team tRDC (2011) nlme: Linear and Nonlinear Mixed Effects Models. R package version 3.1-102 ed.